Agios Pharmaceuticals is halting development of tebapivat, its experimental sickle cell disease drug, after mid-stage results failed to impress.
The company said the Phase 2 candidate “did not demonstrate the level of differentiation required to support continued development.” Agios shares fell about 6.5% to roughly $37.50.
What the mechanism does
Tebapivat was designed as a next-generation pyruvate kinase activator — the same enzyme-boosting approach behind Agios’s approved drug mitapivat.
Pyruvate kinase is a key enzyme in glycolysis, and red blood cells depend on it unusually heavily. They have no mitochondria, having ejected their nucleus and organelles during maturation, so glycolysis is their only source of energy.
Activating the enzyme increases ATP production, which red cells need to maintain membrane integrity and ion balance across a 120-day lifespan spent squeezing through capillaries narrower than they are.
The step matters in sickle cell disease for a second reason. Increased flux through the pathway reduces levels of 2,3-DPG, a molecule that lowers haemoglobin’s oxygen affinity — and sickling occurs when haemoglobin releases oxygen and polymerises. Less 2,3-DPG means haemoglobin holds oxygen more tightly and polymerises less readily.
Why differentiation was the test
The company’s language is precise and worth reading carefully: the drug did not fail on efficacy or safety, it failed to be sufficiently different.
That is a commercial judgement rather than a scientific one. A next-generation compound has to justify displacing the earlier one, and Agios already has mitapivat approved and in development for the same disease.
A successor performing comparably would fragment the company’s own effort and split commercial attention across two products competing for the same patients — which is worse than concentrating on one.
The competitive timing
Rival Novo Nordisk recently reported positive Phase 3 results for its own sickle cell enzyme activator, leaving Agios without the differentiation it had hoped for.
A competitor succeeding in Phase 3 raises the bar for anything arriving later. An entrant now needs to beat an approved drug rather than reach an empty market — and Phase 3 evidence against a Phase 2 candidate is a comparison that favours the incumbent decisively.
Why sickle cell has been difficult
Sickle cell disease is caused by a single well-characterised mutation, and progress has been slower than that clarity suggests.
The disease is variable. Patients with identical genetics differ markedly in severity, influenced by how much fetal haemoglobin they retain and by other modifying factors — which makes trial populations heterogeneous and effects harder to detect.
Endpoints are contested. Pain crises, the most clinically meaningful outcome, are episodic, subjectively reported and influenced by access to care. Haemoglobin level is measurable and its relationship to how patients actually feel is imperfect.
Gene therapies have now been approved and are transformative for those who receive them, requiring intensive conditioning at specialist centres at very high cost — which leaves substantial room for an oral drug, and raises the standard one must meet.
What remains
Agios is not out of sickle cell. Mitapivat is still being developed for the condition, with an FDA decision expected by November 1, and the company continues earlier-stage research.
What sickle cell patients have now
The treatment landscape explains why differentiation is such a demanding standard in this disease.
Hydroxyurea remains the mainstay decades after its introduction. It raises fetal haemoglobin, which does not sickle and interferes with polymerisation of the abnormal adult form, reducing pain crises substantially in patients who respond and tolerate it. It is cheap, oral and imperfect.
Several newer agents arrived over the past decade with different mechanisms, and their real-world impact has been more modest than trial results suggested — one has since been withdrawn over safety findings after approval.
Gene therapies are the transformative option and reach very few people. They require harvesting stem cells, chemotherapy conditioning that carries fertility and malignancy risks, and weeks in a specialist centre, at a price in the millions.
The gap that leaves is a well-tolerated oral drug that meaningfully reduces crises, available to the global population — most of whom live in sub-Saharan Africa and India, where the disease is most common and gene therapy is entirely out of reach. That is the space a new pyruvate kinase activator would occupy, and it is also why merely matching an existing option is not enough.
Concentrating on the approved asset is the coherent response to the situation. Tebapivat’s exit is a reminder that promising mechanisms do not always translate into differentiated medicines. Business news, not medical advice.